Braveheart Bio seeks Nasdaq listing to finance Phase 3 trial of Hengrui rival cardio drug

Braveheart Bio announced it has filed for an initial public offering on the Nasdaq exchange. The company says the capital raised will be used to fund a Phase 3 study of its cardiovascular candidate, which it positions as a rival to a drug being developed by Hengrui and Cytokinetics.

The filing is the fourth biotech IPO submission recorded in the past two weeks, underscoring a growing appetite among emerging companies to tap public markets for development funding.

If the IPO proceeds, the proceeds will enable the company to advance the trial and potentially bring the therapy to market, pending successful results and regulatory approval.